Sorry, you need to enable JavaScript to visit this website.

Advancing Metabolic Research in NASH, Obesity, and Cachexia Through Pfizer’s ASPIRE Program

Did you know that certain metabolic diseases are connected to one another by underlying biological factors? Non-alcoholic steatohepatitis (NASH), obesity, and cachexia are directly linked with heart health, and together they constitute a global public health concern that risks reaching epidemic proportions.

Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

  • Strong immune response shown in both children and adolescents one month after booster dose (month 19) in VLA15-221 study
  • Previously observed high anamnestic antibody response in adults confirmed
  • VLA15 well-tolerated in all age groups following booster dose

August Social Media Round-Up—Financial Update, World Humanitarian Day, RSV Vaccine

August typically brings two things: the dog days of summer and a lot of vacations! Social media tends to be a little quieter than usual, but that doesn’t mean there wasn’t plenty of activity on the Pfizer side of things. Our CEO provided a financial update, we celebrated World Humanitarian Day, and approvals for a pair of important vaccines.

Race Against Resistance: Pfizer takes on AMR

A new film produced for Pfizer by BBC StoryWorks Commercial Productions puts the spotlight on the threat of antimicrobial resistance (AMR), a health crisis with global, and personal, impact. "Race Against Resistance” explores how the rise of antibiotic resistance, the process by which bacteria adapt and mutate to avoid the very drugs designed to kill them, is threatening to undo almost 100 years of progress in medicine. 

July Social Media Round-Up—Rocky Mount Update, Rady Johnson Honored, and Vaccine Progress

Rady Johnson at the 2023 disability:in conference

On July 20, a tornado touched down in North Carolina, injuring 16 people and damaging a Pfizer plant in Rocky Mount, one of the largest manufacturers of sterile injectable drugs in the world. This month’s social media round-up kicks off with a statement from CEO Albert Bourla about the tornado and its impact on Pfizer.

Pfizer Receives Positive CHMP Opinion for Alopecia Areata Treatment

New York, July 21, 2023 — Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for LITFULO™ (ritlecitinib), an oral treatment, recommending marketing authorization of once-daily 50 mg for individuals 12 years of age and older with severe alopecia areata.

Pfizer Receives Positive CHMP Opinion for RSV Vaccine Candidate to Help Protect Infants through Maternal Immunization and Older Adults

•    Pfizer’s RSV vaccine candidate, RSVpreF, would help address substantial burden of RSV disease in individuals 60 years of age and older and in infants from birth through six months of age
•    If approved, Pfizer’s RSV vaccine candidate would be first and only vaccine for both older adults and administration to pregnant individuals to help protect their infants 

Subscribe to Updates